G enomeFrontier Therapeutics, Inc. is an innovation-driven therapeutic company focusing on the development of genetically-engineered cell therapies. Striving to reach the pinnacle in the field of gene therapy, we leveraged four proprietary virus-free gene and cell engineering platforms and successfully created a robust cell engineering Quantum Engine™ that can potentially cure a wide-range of diseases including cancer.

Chimeric antigen receptor T (CAR-T) and T cell receptor T (TCR-T) are genetically-reprogrammed T cells that are used for adoptive immune cell therapy. CAR-T cells recognize cell surface antigens, whereas TCR-T cells recognize endogenous antigens presented in the context of human leukocyte antigen (HLA). Currently, GenomeFrontier Therapeutics Inc. has a number of CAR-T and TCR-T cell products for cancer treatment that are undergoing development using the Quantum Engine™.